Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721044 | 0.90 | BRD4 (0.51) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL17282544 | 0.89 | BRD4 (0.50) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL15556465 | 0.83 | BRD4 (0.49) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL1850782 | 0.81 | BRD4 (0.64) | BRD4PTPN11MAPTSMN1; SMN2HTT | |
| SCHEMBL29086638 | 0.81 | BRD4 (0.43) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL15555565 | 0.81 | BRD4 (0.46) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL15555568 | 0.81 | BRD4 (0.46) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL1372485 | 0.80 | BRD4 (0.49) | BRD4PTPN11DRD2HTR2AHTR7 | |
| SCHEMBL15599366 | 0.79 | BRD4 (0.43) | BRD4PTPN11CYP3A4DRD2SLC6A2 | |
| SCHEMBL29888845 | 0.79 | BRD4 (0.48) | BRD4PTPN11CYP3A4DRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-9181247-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER (US) | 2015-04-16 | — | — | US | disclosed |
| US-8877772-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | UNIVERSITY OF ROCHESTER (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885CYP3A4 4315/4885 |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | BRD4 2773/4885PTPN11 1325/4885CYP3A4 2342/4885 |
| US-20150105401-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885CYP3A4 4315/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | BRD4 583/4885PTPN11 1949/4885CYP3A4 2639/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885CYP3A4 4315/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885CYP3A4 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.